Attendee search 

Sunstone Life Science Ventures’ invests in early-stage Life Science companies in the therapeutic, medical technology and diagnostics fields. Our geographical scope is Europe with particular emphasis on the Nordic countries, Germany and Switzerland.

Our point of entry differs depending on the type of Life Science opportunity. In the therapeutic field, we invest when drug candidates are in the pre-clinical or clinical phase I.  In the areas of medical technology and diagnostics, we tend to invest in companies just before the pivotal clinical trials required to support the intended use and marketing claims.

Sunstone Life Science Ventures investment strategy has a strong industry focus vis-à-vis potential buyers of our portfolio companies. Since we believe that most exits in the Life Science sector will continue to take place in the M&A space, we prefer business models suitable for this exit route. To appear on potential acquirers’ radar screens, we invest in opportunities that have the potential of becoming either a threat or a complement to existing products on the market. We look out for opportunities which target unmet medical needs in commercially attractive markets, and we seek products which, once approved, are likely to receive attractive reimbursement and pricing structures. We have a preference for companies targeting niche markets. In the therapeutic area, opportunities aimed at specialty pharma and orphan drug indications are especially interesting, whereas we consider opportunities aimed at widespread diseases already addressed by established medical treatment regimes less interesting.

We believe that the single most important factor when developing a successful company is the quality of the management team. This is not the same as saying that we only invest in savvy entrepreneurs with a strong track record. But less experienced management teams should be open to change if needed to accelerate the company.   

SEED Capital is the largest early stage venture fund in Denmark. We invest in companies within Medtech and Technologies at the seed or even pre-seed stage from Denmark and southern Sweden. We invest in classic venture companies meaning companies that as a minimum will provide an opportunity for a 10x return on investment. The company should have a highly innovative solution and a scalable business model for entering an attractive market with a number of identified paths to exit.

Because of our strong partnership with the government funded innovation incubator DTU Symbion Innovation we are able to invest €250-750.000 at the early stages of a company’s development, allowing them an opportunity to prove their technology and business.

Depending on capital need, SEED Capital can invest up to €9 million in the following rounds – preferably in syndication with international investors. We take an active advisory role as an investor and will normally take the position of Chairman of the Board in the company until a skilled alternative is identified.

Private equity firm for investments in healthcare companies

SEED Capital is the largest early stage venture fund in Denmark. We invest in companies within Medtech and Technologies at the seed or even pre-seed stage from Denmark and southern Sweden. We invest in classic venture companies meaning companies that as a minimum will provide an opportunity for a 10x return on investment. The company should have a highly innovative solution and a scalable business model for entering an attractive market with a number of identified paths to exit.

Because of our strong partnership with the government funded innovation incubator DTU Symbion Innovation we are able to invest €250-750.000 at the early stages of a company’s development, allowing them an opportunity to prove their technology and business.

Depending on capital need, SEED Capital can invest up to €9 million in the following rounds – preferably in syndication with international investors. We take an active advisory role as an investor and will normally take the position of Chairman of the Board in the company until a skilled alternative is identified.

Private equity firm for investments in healthcare companies

Ferrosan Medical Devices comprises two companies that both provide a range of innovative products used by health care professionals in the fields of surgery and diagnostics. Our technology includes Biomaterials used as haemostatic agent for surgery to control bleeding, and miniature Electromechanics used in devices for minimally invasive surgery and drug delivery.